Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.48 |
| ▸ | TGFBR1 | P36897 | 13/20 | 0.47 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.46 |
| ▸ | CDC7 | O00311 | 1/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.40 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.38 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.38 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25214123 | 0.86 | KMO (0.49) | KDM1AASIC3MAP3K14L3MBTL1CASP3 | |
| SCHEMBL2596864 | 0.84 | TGFBR1 (0.45) | TGFBR1ASIC3MAP3K14CYP3A4CYP2C8 | |
| SCHEMBL31032681 | 0.84 | TGFBR1 (0.45) | TGFBR1ASIC3MAP3K14CYP3A4CYP2C8 | |
| SCHEMBL2596829 | 0.83 | TGFBR1 (0.46) | KDM1ATGFBR1ASIC3 | |
| SCHEMBL30420906 | 0.80 | ASIC3 (0.56) | KDM1ATGFBR1ASIC3L3MBTL1CASP3 | |
| SCHEMBL25011838 | 0.80 | ASIC3 (0.56) | KDM1ATGFBR1ASIC3L3MBTL1CASP3 | |
| SCHEMBL2652006 | 0.76 | CCR1 (0.52) | TGFBR1 | |
| SCHEMBL2596872 | 0.76 | ASIC3 (0.43) | KDM1ATGFBR1ASIC3CYP3A4CYP2C8 | |
| SCHEMBL21055972 | 0.76 | ASIC3 (0.66) | KDM1ATGFBR1ASIC3CDK2 | |
| SCHEMBL30437053 | 0.76 | ASIC3 (0.66) | KDM1ATGFBR1ASIC3CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9073918-B2 | Pyrazolo[4,3-b]pyridine-7-amine inhibitors of ALK5 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-07 | — | — | US | disclosed |
| US-20130324528-A1 | PYRAZOLO[4,3-B]PYRIDINE-7-AMINE INHIBITORS OF ALK5 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-12-05 | — | — | US | disclosed |
| WO-2011146287-A1 | PYRAZOLO[4,3-B]PYRIDINE-7-AMINE INHIBITORS OF ALK5 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130324528-A1 | PYRAZOLO[4,3-B]PYRIDINE-7-AMINE INHIBITORS OF ALK5 | ALK, ALKBH5, ALKBH3 | KDM1A 332/4885TGFBR1 413/4885ASIC3 1070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.